[go: up one dir, main page]

SMT202100516T1 - Modificazione mirata del genoma di ratto - Google Patents

Modificazione mirata del genoma di ratto

Info

Publication number
SMT202100516T1
SMT202100516T1 SM20210516T SMT202100516T SMT202100516T1 SM T202100516 T1 SMT202100516 T1 SM T202100516T1 SM 20210516 T SM20210516 T SM 20210516T SM T202100516 T SMT202100516 T SM T202100516T SM T202100516 T1 SMT202100516 T1 SM T202100516T1
Authority
SM
San Marino
Prior art keywords
targeted modification
rat genome
genome
rat
targeted
Prior art date
Application number
SM20210516T
Other languages
English (en)
Inventor
Ka-Man Venus Lai
Wojtek Auerbach
Alexander Mujica
David Valenzuela
Jeffrey Lee
George Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SMT202100516T1 publication Critical patent/SMT202100516T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D19/00—Instruments or methods for reproduction or fertilisation
    • A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SM20210516T 2013-04-16 2014-04-16 Modificazione mirata del genoma di ratto SMT202100516T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361812319P 2013-04-16 2013-04-16
US201361914768P 2013-12-11 2013-12-11
EP18187581.6A EP3456831B1 (en) 2013-04-16 2014-04-16 Targeted modification of rat genome

Publications (1)

Publication Number Publication Date
SMT202100516T1 true SMT202100516T1 (it) 2021-11-12

Family

ID=51687240

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20180671T SMT201800671T1 (it) 2013-04-16 2014-04-16 Modificazione mirata del genoma di ratto
SM20210516T SMT202100516T1 (it) 2013-04-16 2014-04-16 Modificazione mirata del genoma di ratto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20180671T SMT201800671T1 (it) 2013-04-16 2014-04-16 Modificazione mirata del genoma di ratto

Country Status (26)

Country Link
US (5) US20140310828A1 (it)
EP (2) EP3456831B1 (it)
JP (1) JP6411463B2 (it)
KR (2) KR20200136508A (it)
CN (2) CN105308184B (it)
AU (2) AU2014253942B9 (it)
BR (1) BR112015026197B1 (it)
CA (1) CA2908697C (it)
CY (2) CY1120845T1 (it)
DK (2) DK3456831T3 (it)
ES (2) ES2888250T3 (it)
HK (1) HK1214625A1 (it)
HR (2) HRP20181648T1 (it)
HU (2) HUE056903T2 (it)
IL (2) IL241856B (it)
LT (2) LT2986729T (it)
MX (1) MX369747B (it)
MY (1) MY177850A (it)
PL (2) PL2986729T3 (it)
PT (2) PT3456831T (it)
RS (2) RS58255B1 (it)
RU (1) RU2676708C2 (it)
SG (2) SG10201808935WA (it)
SI (2) SI3456831T1 (it)
SM (2) SMT201800671T1 (it)
WO (1) WO2014172489A2 (it)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018014787A (es) 2010-08-02 2023-02-14 Regeneron Pharma Ratones que producen proteinas de union que comprenden dominios vl.
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
BR112014026294B1 (pt) 2012-04-25 2021-11-23 Regeneron Pharmaceuticals, Inc Método para modificar um lócus genômico alvo em uma célula tronco embrionária (es) de camundongo
NZ714353A (en) 2012-05-25 2017-05-26 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP3611263A1 (en) 2012-12-06 2020-02-19 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
SG11201505968WA (en) 2013-02-20 2015-08-28 Regeneron Pharma Genetic modification of rats
KR102271292B1 (ko) 2013-03-15 2021-07-02 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집의 특이성을 증가시키기 위한 rna-안내 foki 뉴클레아제(rfn)의 용도
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
SMT201800671T1 (it) 2013-04-16 2019-01-11 Regeneron Pharma Modificazione mirata del genoma di ratto
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
US9663782B2 (en) * 2013-07-19 2017-05-30 Larix Bioscience Llc Methods and compositions for producing double allele knock outs
KR102138723B1 (ko) 2013-08-07 2020-07-29 리제너론 파마슈티칼스 인코포레이티드 Lincrna-결핍 비인간 동물
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US20150079680A1 (en) * 2013-09-18 2015-03-19 Kymab Limited Methods, cells & organisms
JP2016536021A (ja) 2013-11-07 2016-11-24 エディタス・メディシン，インコーポレイテッド ＣＲＩＳＰＲ関連方法および支配ｇＲＮＡのある組成物
EP3080279B1 (en) * 2013-12-11 2018-09-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
WO2015184164A1 (en) 2014-05-30 2015-12-03 Regeneron Pharmaceuticals, Inc. Humanized dipeptidyl peptidase iv (dpp4) animals
DK3152312T3 (da) 2014-06-06 2020-04-06 Regeneron Pharma Fremgangsmåder og sammensætninger til modifikation af et mållocus
JP6784601B2 (ja) 2014-06-23 2020-11-11 ザ ジェネラル ホスピタル コーポレイション シークエンシングによって評価されるゲノムワイドでバイアスのないＤＳＢの同定（ＧＵＩＤＥ−Ｓｅｑ）
EP3461885B1 (en) 2014-06-26 2021-10-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
EP3177718B1 (en) 2014-07-30 2022-03-16 President and Fellows of Harvard College Cas9 proteins including ligand-dependent inteins
JP2017536811A (ja) 2014-10-15 2017-12-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 多能性細胞の樹立又は維持のための方法及び組成物
JP6727199B2 (ja) * 2014-11-21 2020-07-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ガイドｒｎａのペアを使用したターゲティングによる遺伝子改変の方法及び組成物
US10900034B2 (en) 2014-12-03 2021-01-26 Agilent Technologies, Inc. Guide RNA with chemical modifications
JP2018500896A (ja) 2014-12-09 2018-01-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化分化抗原群２７４遺伝子を有する非ヒト動物
US11326184B2 (en) * 2014-12-19 2022-05-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification through single-step multiple targeting
WO2016114972A1 (en) 2015-01-12 2016-07-21 The Regents Of The University Of California Heterodimeric cas9 and methods of use thereof
WO2016123243A1 (en) 2015-01-28 2016-08-04 The Regents Of The University Of California Methods and compositions for labeling a single-stranded target nucleic acid
JP6817215B2 (ja) 2015-03-03 2021-01-20 ザ ジェネラル ホスピタル コーポレイション 変更ＰＡＭ特異性を有する遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ
BR112017019620A2 (pt) 2015-03-16 2018-05-15 Regeneron Pharmaceuticals, Inc. ?roedor geneticamente modificado, célula ou tecido, métodos para produção de um roedor geneticamente modificado e de uma população de neurônios motores, métodos para seleção de um agente candidato para modular a disfunção neuronal motora e de um agente candidato para redução do estresse oxidativo em um neurônio motor, ácido nucleico, e, célula de roedor?
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
JP6873911B2 (ja) 2015-04-06 2021-05-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 初代細胞において標的核酸の遺伝子調節を誘導するためにインビトロで行う方法
KR102377189B1 (ko) 2015-05-29 2022-03-22 리제너론 파마슈티칼스 인코포레이티드 C9orf72 유전자좌에서 파괴를 갖는 비-인간 동물
EP3303634B1 (en) 2015-06-03 2023-08-30 The Regents of The University of California Cas9 variants and methods of use thereof
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CA2996888A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Engineered crispr-cas9 nucleases
JP2018526005A (ja) 2015-09-02 2018-09-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 前立腺がんのげっ歯類モデル
CN105177110A (zh) * 2015-09-11 2015-12-23 中国科学院微生物研究所 核酸的检测方法
KR20180043369A (ko) 2015-09-11 2018-04-27 더 제너럴 하스피탈 코포레이션 뉴클레아제 dsb의 완전한 호출 및 시퀀싱(find-seq)
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
JP2018529353A (ja) 2015-09-30 2018-10-11 ザ ジェネラル ホスピタル コーポレイション 配列決定法による切断事象の包括的生体外報告（ＣＩＲＣＬＥ−ｓｅｑ）
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
DK3376857T3 (da) 2015-11-20 2021-05-25 Regeneron Pharma Ikke-humane dyr, der har et humaniseret lymfocyt-aktiveringsgen 3
EP3417061B1 (en) 2016-02-18 2022-10-26 The Regents of the University of California Methods and compositions for gene editing in stem cells
KR102493894B1 (ko) 2016-02-29 2023-01-31 리제너론 파마슈티칼스 인코포레이티드 인간화 tmprss 유전자를 갖는 설치류
EP3429567B1 (en) 2016-03-16 2024-01-10 The J. David Gladstone Institutes Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
BR112018073750A2 (pt) * 2016-05-20 2019-02-26 Regeneron Pharmaceuticals, Inc. métodos para gerar proteínas de ligação ao antígeno contra um antígeno estranho de interesse e para produzir um animal não humano geneticamente modificado com tolerância reduzida de um antígeno estranho de interesse
US20210010022A1 (en) * 2016-05-27 2021-01-14 Cambridge Enterprise Limited Novel nucleic acid construct
KR102598120B1 (ko) 2016-06-03 2023-11-07 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US11572545B2 (en) 2016-06-16 2023-02-07 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
MX2019001211A (es) 2016-07-29 2019-09-16 Regeneron Pharma Ratones que comprenden mutaciones que dan lugar a la expresión de la fibrilina-1 truncada en c.
GB2568182A (en) 2016-08-03 2019-05-08 Harvard College Adenosine nucleobase editors and uses thereof
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN107815465B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
US11279948B2 (en) 2016-08-31 2022-03-22 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric OX40
EP3523426A4 (en) 2016-09-30 2020-01-22 The Regents of The University of California RNA GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHOD FOR USE THEREOF
MX381216B (es) * 2016-09-30 2025-03-12 Regeneron Pharma Animales no humanos que tienen una expansion de repeticiones de hexanucleotidos en un locus c9orf72.
US10669539B2 (en) 2016-10-06 2020-06-02 Pioneer Biolabs, Llc Methods and compositions for generating CRISPR guide RNA libraries
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
CA3045134A1 (en) 2016-12-14 2018-06-21 Ligandal, Inc. Compositions and methods for nucleic acid and/or protein payload delivery
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
CN118140872A (zh) 2017-01-19 2024-06-07 欧莫诺艾比公司 来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体
CA3051442A1 (en) 2017-02-14 2018-08-23 Alejandro Soto-Gutierrez Methods of engineering human induced pluripotent stem cells to produce liver tissue
EP3585158B1 (en) 2017-02-27 2023-07-05 Regeneron Pharmaceuticals, Inc. Rodent models of retinoschisis
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
CN108467873B (zh) * 2017-03-17 2020-03-13 百奥赛图江苏基因生物技术有限公司 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用
CN110914426A (zh) 2017-03-23 2020-03-24 哈佛大学的校长及成员们 包含核酸可编程dna结合蛋白的核碱基编辑器
CN106987604B (zh) * 2017-03-29 2021-05-28 北京希诺谷生物科技有限公司 一种制备动脉粥样硬化疾病模型犬的方法
EP3612631A4 (en) 2017-04-20 2021-01-13 Ramot at Tel-Aviv University Ltd. RECOMBINATION ACTIVATING GENE (RAG) INDUCED V (D) J GENE TARGETING
CA3059956A1 (en) 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
CA3063449A1 (en) 2017-05-25 2018-11-29 The General Hospital Corporation Using split deaminases to limit unwanted off-target base editor deamination
CN109136273B (zh) * 2017-06-16 2022-09-27 中国科学院分子细胞科学卓越创新中心 制备免疫缺陷的大鼠的方法及其应用
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019028032A1 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. EMBRYONIC STEM CELLS OF TRANSGENIC MOUSE CASES AND MICE AND USES THEREOF
MX2020001177A (es) 2017-07-31 2020-09-25 Regeneron Pharma Animales no humanos reporteros de crispr y usos de los mismos.
EP3672612A4 (en) 2017-08-23 2021-09-29 The General Hospital Corporation MANIPULATED CRISPR-CAS9-NUCLEASES WITH CHANGED PAM SPECIFICITY
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
US20190119701A1 (en) * 2017-09-08 2019-04-25 Life Technologies Corporation Methods for improved homologous recombination and compositions thereof
CN118581083A (zh) * 2017-09-28 2024-09-03 株式会社图尔金 用于基因表达调节的人工基因组操纵
US11572574B2 (en) 2017-09-28 2023-02-07 Toolgen Incorporated Artificial genome manipulation for gene expression regulation
ES2962277T3 (es) 2017-09-29 2024-03-18 Regeneron Pharma Roedores que comprenden un locus Ttr humanizado y métodos de uso
CA3077251A1 (en) * 2017-09-29 2019-04-04 Intellia Therapeutics, Inc. Compositions and methods for ttr gene editing and treating attr amyloidosis
EP4249502A3 (en) 2017-09-29 2023-12-06 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized c1q complex
WO2019075197A1 (en) 2017-10-11 2019-04-18 The General Hospital Corporation METHODS OF DETECTION OF INDIVIDUAL SITE-SPECIFIC PARASITE GENOMIC DEAMINATION BY BASE EDITING TECHNOLOGIES
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. USES OF BASIC EDITORS ADENOSINE
US11419318B2 (en) 2017-11-30 2022-08-23 Regeneran Pharmaceuticals, Inc. Genetically modified rat comprising a humanized TRKB locus
BR112020011184A2 (pt) 2017-12-05 2020-11-17 Regeneron Pharmaceuticals, Inc. roedor geneticamente modificado, células de roedor isolada, célula imortalizada, embrião de roedor, uso de um roedor, célula b isolada, anticorpo preparado por um método, métodos para produzir um roedor geneticamente modificado, um anticorpo, uma cadeia pesada totalmente humana ou uma cadeia leve totalmente humana, uma sequência nucleotídica, para gerar uma ¿ sequência de domínio variável de cadeia pesada ou leve humana e gerar uma ¿ sequência da região variável de cadeia pesada ou leve humana, célula-tronco embrionária, célula es de roedor, e, célula es isolada de roedor.
EP3592140A1 (en) 2018-03-19 2020-01-15 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
EP3772927B1 (en) 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CN112105260B (zh) 2018-03-26 2023-04-28 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
EP3775229A4 (en) * 2018-03-27 2021-12-15 The Trustees Of The University Of Pennsylvania MODIFIED IMMUNE CELLS WITH IMPROVED FUNCTION AND SCREENING METHODS TO IDENTIFY THEM
EP3781585A4 (en) 2018-04-17 2022-01-26 The General Hospital Corporation SENSITIVE IN VITRO TESTS FOR SUBSTRATE PREFERENCES AND SITE FOR NUCLEIC ACID BINDERS, MODIFIERS AND CLEAVAGE AGENTS
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
CN109868285A (zh) * 2018-05-29 2019-06-11 江苏艾尔康生物医药科技有限公司 一种免疫缺陷大鼠动物模型的构建方法及应用
US10463029B1 (en) 2018-06-07 2019-11-05 Regeneron Pharmaceuticals, Inc. Rodent model of steel syndrome
WO2019241350A1 (en) 2018-06-13 2019-12-19 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
WO2020014528A1 (en) 2018-07-13 2020-01-16 The Regents Of The University Of California Retrotransposon-based delivery vehicle and methods of use thereof
IL315703A (en) 2018-07-16 2024-11-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
BR112021003380A2 (pt) * 2018-08-28 2021-05-18 Flagship Pioneering Innovations Vi, Llc métodos e composições para modulação de um genoma
CN112969367B (zh) 2018-09-13 2023-04-07 瑞泽恩制药公司 作为c3肾小球病模型的补体因子h基因敲除大鼠
US11407995B1 (en) 2018-10-26 2022-08-09 Inari Agriculture Technology, Inc. RNA-guided nucleases and DNA binding proteins
US11434477B1 (en) 2018-11-02 2022-09-06 Inari Agriculture Technology, Inc. RNA-guided nucleases and DNA binding proteins
CN109504708A (zh) * 2018-12-03 2019-03-22 江苏集萃药康生物科技有限公司 一种筛选标记自我删除的基因打靶载体及方法
SG11202105189RA (en) 2018-12-20 2021-06-29 Regeneron Pharma Nuclease-mediated repeat expansion
WO2020150426A1 (en) 2019-01-17 2020-07-23 Regeneron Pharmaceuticals, Inc. A rodent model of mood disorders
US11946040B2 (en) 2019-02-04 2024-04-02 The General Hospital Corporation Adenine DNA base editor variants with reduced off-target RNA editing
WO2020163856A1 (en) 2019-02-10 2020-08-13 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Modified mitochondrion and methods of use thereof
CN112400022B (zh) * 2019-02-18 2023-06-30 百奥赛图(北京)医药科技股份有限公司 具有人源化免疫球蛋白基因座的经遗传修饰的非人动物
CA3131145A1 (en) * 2019-02-21 2020-08-27 Nemametrix Inc Monogenic or polygenic disease model organisms humanized with two or more genes
WO2020172505A1 (en) 2019-02-22 2020-08-27 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
DE212020000516U1 (de) 2019-03-07 2022-01-17 The Regents of the University of California CRISPR-CAS-Effektorpolypeptide
CN113543634A (zh) 2019-03-15 2021-10-22 雷杰纳荣制药公司 溶质载体39成员5的功能丧失啮齿动物模型
KR20210143230A (ko) 2019-03-19 2021-11-26 더 브로드 인스티튜트, 인코퍼레이티드 뉴클레오티드 서열을 편집하기 위한 방법 및 조성물
SG11202108454RA (en) 2019-04-04 2021-09-29 Regeneron Pharma Non-human animals comprising a humanized coagulation factor 12 locus
EP3801011A1 (en) 2019-06-04 2021-04-14 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
MX2021014893A (es) 2019-06-05 2022-03-11 Regeneron Pharma Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos.
CA3137764A1 (en) 2019-06-07 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized albumin locus
CN114008193A (zh) 2019-06-27 2022-02-01 瑞泽恩制药公司 Tdp-43蛋白病的建模
AU2020358847A1 (en) 2019-10-03 2022-04-21 Regeneron Pharmaceuticals, Inc. A Crnn loss of function rodent model
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
CN114786479B (zh) * 2019-12-25 2023-12-15 江苏集萃药康生物科技股份有限公司 一种il-15人源化小鼠模型及其用途
EP4093863A4 (en) 2020-01-24 2024-04-10 The General Hospital Corporation CRISPR-CAS ENZYMES WITH IMPROVED ON-TARGET ACTIVITY
CN115175559A (zh) 2020-01-28 2022-10-11 瑞泽恩制药公司 包含人源化pnpla3基因座的非人动物及其使用方法
US20230081547A1 (en) 2020-02-07 2023-03-16 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized klkb1 locus and methods of use
US20210274759A1 (en) 2020-03-04 2021-09-09 Regeneron Pharmaceuticals, Inc. A rodent model of b4galt1-mediated functions
CN113355323B (zh) * 2020-03-06 2023-07-11 生物岛实验室 人源化ace2基因改造小鼠模型的制备方法及应用
CN113355325B (zh) * 2020-03-06 2023-07-14 中国科学院广州生物医药与健康研究院 人源化ace2基因改造小鼠胚胎干细胞模型制备方法及应用
US20230102342A1 (en) 2020-03-23 2023-03-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
KR20230004472A (ko) 2020-04-21 2023-01-06 리제너론 파마슈티칼스 인코포레이티드 인간화 cxcl13 유전자를 갖는 비인간 동물
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
AU2021283564A1 (en) 2020-06-02 2022-12-08 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
KR20230078677A (ko) 2020-10-01 2023-06-02 리제너론 파마슈티칼스 인코포레이티드 인간 cr1을 발현하는 설치류 동물
US20220192165A1 (en) 2020-12-21 2022-06-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene
CN112852875B (zh) * 2021-02-26 2022-10-21 福建省立医院 示踪肿瘤T淋巴细胞浸润的CD3e转基因小鼠模型的构建方法
CN113229213B (zh) * 2021-05-14 2022-06-14 福州大学 通过近红外荧光探针标记血栓实现肺栓塞造模及无创定量检测的方法
EP4399294A1 (en) 2021-09-10 2024-07-17 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
JP2024545127A (ja) 2021-12-08 2024-12-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 変異ミオシリン疾患モデル及びその使用
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
EP4475671A1 (en) 2022-02-07 2024-12-18 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
KR20240144138A (ko) 2022-02-11 2024-10-02 리제너론 파마슈티칼스 인코포레이티드 4r 타우 표적화제를 스크리닝하기 위한 조성물 및 방법
EP4514125A1 (en) 2022-04-26 2025-03-05 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
EP4531554A1 (en) 2022-05-31 2025-04-09 Regeneron Pharmaceuticals, Inc. Animal model of tdp-43 proteinopathy
US20230417899A1 (en) 2022-06-27 2023-12-28 Oshkosh Corporation Position tracking for a lift device
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024020057A1 (en) 2022-07-19 2024-01-25 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
US20240224964A9 (en) 2022-09-29 2024-07-11 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
CN116326540A (zh) * 2022-12-22 2023-06-27 新疆农业大学 一种调控哺乳期马驹肠道健康并促进生长发育的补饲方法
US20240415103A1 (en) 2023-06-16 2024-12-19 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome

Family Cites Families (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87133B (pt) 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
EP0716690A1 (en) 1993-08-30 1996-06-19 Northwestern University Rat pluripotent embryonic stem cells and method of obtaining and using same
WO1997030151A1 (en) 1996-02-16 1997-08-21 The University Of Edinburgh Cytokine expressed by dia/lif-deficient embryonic stem cells for the inhibition of differentiation
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US6136566A (en) 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
WO1999005266A2 (en) 1997-07-26 1999-02-04 Wisconsin Alumni Research Foundation Trans-species nuclear transfer
WO2000039316A1 (en) * 1998-12-31 2000-07-06 The J. David Gladstone Institutes Transgenic rodents and rodent cell lines expressing hiv co-receptors
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
CA2361191A1 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
IL150069A0 (en) 1999-12-06 2002-12-01 Sangamo Biosciences Inc Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002228841C1 (en) 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
WO2002059263A2 (en) 2000-12-19 2002-08-01 Sunol Molecular Corporation Transgenic animals comprising a humanized immune system
US7273923B2 (en) 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
WO2002057308A2 (en) 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Zinc finger polypeptides and their use
NZ527527A (en) 2001-02-14 2005-08-26 Leo T Mammalian multipotent adult stem cells (MASC) with the capacity to differentiate into cells of mesodermal, ectodermal or endodermal origin and uses thereof
AUPR451401A0 (en) 2001-04-20 2001-05-24 Monash University A method of nuclear transfer
CN100575485C (zh) 2002-01-23 2009-12-30 犹他大学研究基金会 使用锌指核酸酶的定向染色体诱变
WO2003078619A1 (en) 2002-03-15 2003-09-25 Cellectis Hybrid and single chain meganucleases and use thereof
EP2368982A3 (en) 2002-03-21 2011-10-12 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7612250B2 (en) 2002-07-29 2009-11-03 Trustees Of Tufts College Nuclear transfer embryo formation method
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
WO2004031346A2 (en) 2002-09-06 2004-04-15 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US20030175968A1 (en) 2002-10-30 2003-09-18 Golic Kent G. Gene targeting method
US7344886B2 (en) 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
WO2004063356A2 (en) 2003-01-13 2004-07-29 Rao Mahendra S Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
WO2005001087A2 (en) 2003-06-11 2005-01-06 Regeneron Pharmaceuticals, Inc. Methods of modifying genes in eukaryotic cells
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
JP4862119B2 (ja) 2004-03-04 2012-01-25 大日本住友製薬株式会社 ラット胚性幹細胞
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
US20090104158A1 (en) 2004-09-03 2009-04-23 Moraga Biotechnology Corporation Non-Embryonic Totipotent Blastomere-Like Stem Cells And Methods Therefor
AU2005287278B2 (en) 2004-09-16 2011-08-04 Sangamo Biosciences, Inc. Compositions and methods for protein production
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
FR2879622B1 (fr) 2004-12-17 2008-02-01 Agronomique Inst Nat Rech Procede in vitro de production d'ovocytes ou d'oeufs presentant une modification genomique ciblee
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
EP2327772A1 (en) 2005-03-15 2011-06-01 Cellectis I-crel meganuclease variants with modified specificity, method of preparation and uses thereof
US10022457B2 (en) 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
GB0615327D0 (en) * 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
CA2645170A1 (en) 2006-03-30 2007-10-11 The University Court Of The University Of Edinburgh Culture medium containing kinase inhibitors, and uses thereof
US7910798B2 (en) * 2006-03-31 2011-03-22 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CN101117633B (zh) 2006-08-03 2011-07-20 上海交通大学附属儿童医院 一种细胞核移植方法
DK2092068T3 (en) 2006-12-14 2015-01-12 Dow Agrosciences Llc Optimized non-canonical zinc finger proteins
US7771967B2 (en) * 2006-12-22 2010-08-10 The J. David Gladstone Institutes Nucleic acid encoding apolipoprotein E-I3
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
ATE489465T1 (de) 2007-04-26 2010-12-15 Sangamo Biosciences Inc Gezielte integration in die ppp1r12c-position
LT2602323T (lt) 2007-06-01 2018-04-10 Open Monoclonal Technology, Inc. Kompozicijos ir būdai endogeninių imunoglobulinų genams slopinti ir transgeniniams žmogaus idiotipo antikūnams gaminti
CA2734235C (en) 2008-08-22 2019-03-26 Sangamo Biosciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
EP2180058A1 (en) 2008-10-23 2010-04-28 Cellectis Meganuclease recombination system
JP5681114B2 (ja) * 2008-12-04 2015-03-04 サンガモ バイオサイエンシーズ， インコーポレイテッド 亜鉛フィンガーヌクレアーゼを使用したラットのゲノム編集
US20110030072A1 (en) 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
SG172160A1 (en) 2008-12-17 2011-07-28 Scripps Research Inst Generation and maintenance of stem cells
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
CA2755192C (en) 2009-03-20 2018-09-11 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
EP2421980A2 (en) 2009-04-23 2012-02-29 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for cancer
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
US9314005B2 (en) 2009-07-01 2016-04-19 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for severe combined immunodeficiency (SCID)
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
US8558055B2 (en) 2009-07-24 2013-10-15 Transposagen Biopharmaceuticals, Inc. Genetically modified rat comprising a cytokine gene disruption and exhibiting a greater susceptibility to a cytokine-mediated autoimmune and/or inflammatory disease
JP2013500018A (ja) 2009-07-24 2013-01-07 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー ゲノム編集のための方法
WO2011017293A2 (en) 2009-08-03 2011-02-10 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
US8518392B2 (en) 2009-08-14 2013-08-27 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
EP2493288B1 (en) 2009-10-28 2015-02-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Homologous recombination in the oocyte
PT2494047T (pt) 2009-10-29 2017-02-08 Regeneron Pharma Alelos multifuncionais
WO2011053957A2 (en) 2009-11-02 2011-05-05 Gen9, Inc. Compositions and methods for the regulation of multiple genes of interest in a cell
JP5807862B2 (ja) 2009-12-01 2015-11-10 国立研究開発法人国立がん研究センター ラット胚性幹細胞を用いたキメララットの作製法
PT2510096E (pt) 2009-12-10 2015-02-04 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
US20130023051A1 (en) 2009-12-21 2013-01-24 Keygene N.V. Techniques for transfecting protoplasts
AU2011207387B2 (en) 2010-01-22 2015-02-26 Corteva Agriscience Llc Excision of transgenes in genetically modified organisms
EP2660318A1 (en) 2010-02-09 2013-11-06 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
KR101953237B1 (ko) 2010-05-17 2019-02-28 상가모 테라퓨틱스, 인코포레이티드 신규 dna 결합 단백질 및 이의 용도
GB201009732D0 (en) 2010-06-10 2010-07-21 Gene Bridges Gmbh Direct cloning
WO2011156723A1 (en) 2010-06-11 2011-12-15 Regeneron Pharmaceuticals, Inc. Production of fertile xy female animals from xy es cells
AU2011281062B2 (en) 2010-07-21 2015-01-22 Board Of Regents, The University Of Texas System Methods and compositions for modification of a HLA locus
WO2012018726A1 (en) 2010-08-02 2012-02-09 Cellectis Sa Method for increasing double-strand break-induced gene targeting
US9402377B2 (en) 2010-09-20 2016-08-02 Yale University Human SIRPAalpha transgenic animals and their methods of use
KR102585058B1 (ko) 2011-02-15 2023-10-05 리제너론 파마슈티칼스 인코포레이티드 인간화된 ｍ－ｃｓｆ 마우스
WO2012129198A1 (en) * 2011-03-23 2012-09-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for obesity and diabetes
US20140304847A1 (en) 2011-06-07 2014-10-09 Ralf Kühn Recombination efficiency by inhibition of nhej dna repair
PL2747551T3 (pl) * 2011-08-26 2020-09-21 Yecuris Corporation Szczury z niedoborem hydrolazy fumaryloacetooctanowej (fah) i z niedoborem odporności oraz ich zastosowanie
LT2771357T (lt) 2011-10-28 2018-10-25 Regeneron Pharmaceuticals, Inc. Pelės su genetiškai modifikuotu t ląstelių receptoriumi
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
BR112014026294B1 (pt) 2012-04-25 2021-11-23 Regeneron Pharmaceuticals, Inc Método para modificar um lócus genômico alvo em uma célula tronco embrionária (es) de camundongo
DE102012103797A1 (de) 2012-04-30 2013-10-31 KRAH Elektronische Bauelemente GmbH Flüssigkeitsgekühlter Widerstand
AU2013259647B2 (en) 2012-05-07 2018-11-08 Corteva Agriscience Llc Methods and compositions for nuclease-mediated targeted integration of transgenes
NZ714353A (en) 2012-05-25 2017-05-26 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP2858486A4 (en) 2012-06-12 2016-04-13 Hoffmann La Roche METHOD AND COMPOSITIONS FOR GENERATING ALLELES WITH CONDITIONAL KNOCKOUT
CN105188767A (zh) 2012-07-25 2015-12-23 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
KR101656236B1 (ko) 2012-10-23 2016-09-12 주식회사 툴젠 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
EP3611263A1 (en) 2012-12-06 2020-02-19 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
WO2014093479A1 (en) 2012-12-11 2014-06-19 Montana State University Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation
EP2931892B1 (en) 2012-12-12 2018-09-12 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20140189896A1 (en) 2012-12-12 2014-07-03 Feng Zhang Crispr-cas component systems, methods and compositions for sequence manipulation
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
ES2658401T3 (es) 2012-12-12 2018-03-09 The Broad Institute, Inc. Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas
US20140242664A1 (en) 2012-12-12 2014-08-28 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
CA2894684A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
CA2895155C (en) 2012-12-17 2021-07-06 President And Fellows Of Harvard College Rna-guided human genome engineering
US10995338B2 (en) 2012-12-27 2021-05-04 Keygene N.V. Method for removing genetic linkage in a plant
WO2014127287A1 (en) 2013-02-14 2014-08-21 Massachusetts Institute Of Technology Method for in vivo tergated mutagenesis
SG11201505968WA (en) 2013-02-20 2015-08-28 Regeneron Pharma Genetic modification of rats
EP2958996B1 (en) 2013-02-25 2019-10-16 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
WO2014131833A1 (en) 2013-02-27 2014-09-04 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Gene editing in the oocyte by cas9 nucleases
US10612043B2 (en) 2013-03-09 2020-04-07 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events
US9260752B1 (en) 2013-03-14 2016-02-16 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
WO2014165825A2 (en) 2013-04-04 2014-10-09 President And Fellows Of Harvard College Therapeutic uses of genome editing with crispr/cas systems
US20160040155A1 (en) 2013-04-16 2016-02-11 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
SMT201800671T1 (it) 2013-04-16 2019-01-11 Regeneron Pharma Modificazione mirata del genoma di ratto
US20160186208A1 (en) 2013-04-16 2016-06-30 Whitehead Institute For Biomedical Research Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
EP2796558A1 (en) 2013-04-23 2014-10-29 Rheinische Friedrich-Wilhelms-Universität Bonn Improved gene targeting and nucleic acid carrier molecule, in particular for use in plants
US10604771B2 (en) 2013-05-10 2020-03-31 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
EP3730615A3 (en) 2013-05-15 2020-12-09 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
JP7065564B2 (ja) 2013-05-29 2022-05-12 セレクティス Ｃａｓ９ニッカーゼ活性を用いて正確なｄｎａ切断をもたらすための方法
ES2883131T3 (es) 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
ES2645393T3 (es) 2013-05-29 2017-12-05 Cellectis Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN
US20140359795A1 (en) 2013-05-31 2014-12-04 Recombinetics, Inc. Genetic techniques for making animals with sortable sperm
WO2014201015A2 (en) 2013-06-11 2014-12-18 The Regents Of The University Of California Methods and compositions for target dna modification
KR20160044457A (ko) 2013-06-17 2016-04-25 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 탠덤 안내 시스템, 방법 및 조성물의 전달, 조작 및 최적화
EP3011032B1 (en) 2013-06-17 2019-10-16 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
JP6665088B2 (ja) 2013-06-17 2020-03-13 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物
JP6702858B2 (ja) 2013-06-17 2020-06-03 ザ・ブロード・インスティテュート・インコーポレイテッド ウイルス成分を使用して障害および疾患をターゲティングするためのＣＲＩＳＰＲ−Ｃａｓ系および組成物の送達、使用および治療上の適用
EP3825406A1 (en) 2013-06-17 2021-05-26 The Broad Institute Inc. Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
EP3011035B1 (en) 2013-06-17 2020-05-13 The Broad Institute, Inc. Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
AU2014281472A1 (en) 2013-06-19 2016-01-21 Sigma-Aldrich Co. Llc. Targeted integration
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
US11459585B2 (en) 2013-07-09 2022-10-04 President And Fellows Of Harvard College Multiplex RNA-guided genome engineering
EP3019595A4 (en) 2013-07-09 2016-11-30 THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS
AU2014287397B2 (en) 2013-07-10 2019-10-10 President And Fellows Of Harvard College Orthogonal Cas9 proteins for RNA-guided gene regulation and editing
US9663782B2 (en) 2013-07-19 2017-05-30 Larix Bioscience Llc Methods and compositions for producing double allele knock outs
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
CA2922090C (en) 2013-08-22 2021-05-18 Pioneer Hi-Bred International, Inc. Genome modification using guide polynucleotide/cas endonuclease systems and methods of use
KR20160060659A (ko) 2013-08-29 2016-05-30 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Hiv 감염증의 rna-유도 치료를 위한 방법 및 조성물
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US20150079680A1 (en) 2013-09-18 2015-03-19 Kymab Limited Methods, cells & organisms
US10822606B2 (en) 2013-09-27 2020-11-03 The Regents Of The University Of California Optimized small guide RNAs and methods of use
WO2015052231A2 (en) 2013-10-08 2015-04-16 Technical University Of Denmark Multiplex editing system
CN116836957A (zh) 2013-10-17 2023-10-03 桑格摩生物科学股份有限公司 用于核酸酶介导的基因组工程改造的递送方法和组合物
EP3865575A1 (en) 2013-11-06 2021-08-18 Hiroshima University Vector for nucleic acid insertion
JP2016536021A (ja) 2013-11-07 2016-11-24 エディタス・メディシン，インコーポレイテッド ＣＲＩＳＰＲ関連方法および支配ｇＲＮＡのある組成物
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
US10450586B2 (en) 2013-11-28 2019-10-22 Horizon Discovery Limited Somatic haploid human cell line
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
EP3080259B1 (en) 2013-12-12 2023-02-01 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
BR112016013201B1 (pt) 2013-12-12 2023-01-31 The Broad Institute, Inc. Uso de uma composição compreendendo um sistema crispr-cas no tratamento de uma doença genética ocular
JP2017503485A (ja) 2013-12-12 2017-02-02 ザ・ブロード・インスティテュート・インコーポレイテッド 遺伝子産物の発現、構造情報、及び誘導性モジュラーｃａｓ酵素を変更するためのｃｒｉｓｐｒ−ｃａｓ系並びに方法
CN106029880A (zh) 2013-12-12 2016-10-12 布罗德研究所有限公司 核苷酸重复障碍中CRISPR-Cas系统的组合物和使用方法
AU2014361784A1 (en) 2013-12-12 2016-06-23 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders
BR112016013213A2 (pt) 2013-12-12 2017-12-05 Massachusetts Inst Technology administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para visar distúrbios e doenças usando componentes de administração de partículas
US20160312233A1 (en) 2013-12-13 2016-10-27 Cellectis New method of selection of algal-transformed cells using nuclease
AU2014368982B2 (en) 2013-12-19 2021-03-25 Amyris, Inc. Methods for genomic integration
SG10201805815YA (en) 2014-01-08 2018-08-30 Harvard College Rna-guided gene drives
WO2015112790A2 (en) 2014-01-24 2015-07-30 Children's Medical Center Corporation High-throughput mouse model for optimizing antibody affinities
WO2015116969A2 (en) 2014-01-30 2015-08-06 The Board Of Trustees Of The University Of Arkansas Method, vectors, cells, seeds and kits for stacking genes into a single genomic site
WO2015117041A1 (en) 2014-01-30 2015-08-06 Nair Ramesh B Gene modification-mediated methods and compositions for generating dominant traits in eukaryotic systems
ES2802984T3 (es) 2014-02-11 2021-01-22 Univ Colorado Regents Ingeniería del genoma multiplex mediante CRISPR
JP6606088B2 (ja) 2014-02-24 2019-11-13 サンガモ セラピューティクス， インコーポレイテッド ヌクレアーゼ媒介性標的化組み込みのための方法および組成物
US11028388B2 (en) 2014-03-05 2021-06-08 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
WO2015138510A1 (en) 2014-03-10 2015-09-17 Editas Medicine., Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
CA2942268A1 (en) 2014-03-12 2015-09-17 Precision Biosciences, Inc. Dystrophin gene exon deletion using engineered nucleases
PL3116305T3 (pl) 2014-03-14 2024-04-22 Cibus Us Llc Sposoby i kompozycje do zwiększania wydajności celowanej modyfikacji genów z użyciem naprawy genów, w której pośredniczą oligonukleotydy
EP3119878B1 (en) 2014-03-18 2021-05-26 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression
US10349639B2 (en) 2014-03-26 2019-07-16 University Of Maryland, College Park Targeted genome editing in zygotes of domestic large animals
GB201406968D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Deletion mutants
WO2015163733A1 (en) 2014-04-24 2015-10-29 Institute For Basic Science A method of selecting a nuclease target sequence for gene knockout based on microhomology
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
WO2015173436A1 (en) 2014-05-16 2015-11-19 Vrije Universiteit Brussel Genetic correction of myotonic dystrophy type 1
CN107002094A (zh) 2014-05-30 2017-08-01 斯坦福大学托管董事会 用于治疗潜伏病毒感染的组合物和方法
DK3152312T3 (da) 2014-06-06 2020-04-06 Regeneron Pharma Fremgangsmåder og sammensætninger til modifikation af et mållocus
ES2788426T3 (es) 2014-06-16 2020-10-21 Univ Johns Hopkins Composiciones y métodos para la expresión de ARNs de guía de CRISPR utilizando el promotor de H1
EP3461885B1 (en) 2014-06-26 2021-10-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
WO2016011210A2 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US9944933B2 (en) 2014-07-17 2018-04-17 Georgia Tech Research Corporation Aptamer-guided gene targeting
WO2016011428A1 (en) 2014-07-17 2016-01-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating cells containing fusion genes
WO2016033315A2 (en) 2014-08-27 2016-03-03 New England Biolabs, Inc. Synthon formation
EP3186376B1 (en) 2014-08-27 2019-03-20 Caribou Biosciences, Inc. Methods for increasing cas9-mediated engineering efficiency
US10570418B2 (en) 2014-09-02 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification
CA2957793A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049024A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
SG11201702074VA (en) 2014-09-29 2017-04-27 Jackson Lab High efficiency, high throughput generation of genetically modified mammals by electroporation
KR102630014B1 (ko) 2014-10-01 2024-01-25 더 제너럴 하스피탈 코포레이션 뉴클레아제-유도 상동성-지정 복구의 효율 증가 방법
CA2963693A1 (en) 2014-10-10 2016-04-14 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2016061073A1 (en) 2014-10-14 2016-04-21 Memorial Sloan-Kettering Cancer Center Composition and method for in vivo engineering of chromosomal rearrangements
JP2017536811A (ja) 2014-10-15 2017-12-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 多能性細胞の樹立又は維持のための方法及び組成物
CA2964796C (en) 2014-10-17 2022-01-11 The Penn State Research Foundation Methods and compositions for multiplex rna guided genome editing and other rna technologies
EP3207131B1 (en) 2014-10-17 2022-09-28 Howard Hughes Medical Institute Genomic probes
WO2016065364A1 (en) 2014-10-24 2016-04-28 Life Technologies Corporation Compositions and methods for enhancing homologous recombination
EP3215623A4 (en) 2014-11-06 2018-09-26 President and Fellows of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
CA2963820A1 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
JP6727199B2 (ja) 2014-11-21 2020-07-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ガイドｒｎａのペアを使用したターゲティングによる遺伝子改変の方法及び組成物
CA2968808A1 (en) 2014-11-27 2016-06-02 Danziger Innovations Ltd. Nucleic acid constructs for genome editing
WO2016089866A1 (en) 2014-12-01 2016-06-09 President And Fellows Of Harvard College Rna-guided systems for in vivo gene editing
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
EP3230452A1 (en) 2014-12-12 2017-10-18 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016097751A1 (en) 2014-12-18 2016-06-23 The University Of Bath Method of cas9 mediated genome engineering
US11326184B2 (en) 2014-12-19 2022-05-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification through single-step multiple targeting
US10190106B2 (en) 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
WO2016108926A1 (en) 2014-12-30 2016-07-07 The Broad Institute Inc. Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
WO2016112242A1 (en) 2015-01-08 2016-07-14 President And Fellows Of Harvard College Split cas9 proteins
CN107406842B (zh) 2015-01-09 2021-05-11 生物辐射实验室股份有限公司 检测基因组编辑
WO2016114972A1 (en) 2015-01-12 2016-07-21 The Regents Of The University Of California Heterodimeric cas9 and methods of use thereof
WO2016115326A1 (en) 2015-01-15 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating genome editing
GB2550745A (en) 2015-01-28 2017-11-29 Pioneer Hi Bred Int Crispr hybrid DNA/RNA Polynucleotides and methods of use
WO2016130697A1 (en) 2015-02-11 2016-08-18 Memorial Sloan Kettering Cancer Center Methods and kits for generating vectors that co-express multiple target molecules
EP3262171A2 (en) 2015-02-23 2018-01-03 Crispr Therapeutics AG Materials and methods for treatment of hemoglobinopathies
WO2016135559A2 (en) 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
CA2977685C (en) 2015-03-02 2024-02-20 Sinai Health System Homologous recombination factors
GB201504223D0 (en) 2015-03-12 2015-04-29 Genome Res Ltd Biallelic genetic modification
US20160281111A1 (en) 2015-03-26 2016-09-29 Editas Medicine, Inc. Crispr/cas-mediated gene conversion
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems

Also Published As

Publication number Publication date
RS58255B1 (sr) 2019-03-29
EP3456831A1 (en) 2019-03-20
US20140310828A1 (en) 2014-10-16
CN111500630A (zh) 2020-08-07
BR112015026197B1 (pt) 2022-12-06
WO2014172489A2 (en) 2014-10-23
RU2676708C2 (ru) 2019-01-10
PT3456831T (pt) 2021-09-10
US20190323032A1 (en) 2019-10-24
HK1214625A1 (zh) 2016-07-29
ES2888250T3 (es) 2022-01-03
EP2986729A2 (en) 2016-02-24
US20170204430A1 (en) 2017-07-20
IL241856B (en) 2020-09-30
EP2986729B1 (en) 2018-09-19
WO2014172489A3 (en) 2014-12-11
SMT201800671T1 (it) 2019-01-11
PL3456831T3 (pl) 2021-12-06
KR20150141987A (ko) 2015-12-21
DK2986729T3 (en) 2018-10-29
DK3456831T3 (da) 2021-09-06
IL276772A (en) 2020-10-29
JP2016515401A (ja) 2016-05-30
MX369747B (es) 2019-11-20
HRP20211385T1 (hr) 2021-12-10
AU2014253942A1 (en) 2015-11-12
SG10201808935WA (en) 2018-11-29
LT2986729T (lt) 2018-10-25
HRP20181648T1 (hr) 2019-01-25
RS62263B1 (sr) 2021-09-30
JP6411463B2 (ja) 2018-10-24
US12037596B2 (en) 2024-07-16
NZ713343A (en) 2021-08-27
MX2015014487A (es) 2016-07-28
RU2015148637A (ru) 2017-05-22
CN105308184B (zh) 2020-06-02
SI2986729T1 (sl) 2019-02-28
US20140309487A1 (en) 2014-10-16
HRP20211385T8 (hr) 2022-03-04
ES2699578T3 (es) 2019-02-11
MY177850A (en) 2020-09-23
CY1120845T1 (el) 2019-12-11
LT3456831T (lt) 2021-09-10
HUE056903T2 (hu) 2022-04-28
PL2986729T3 (pl) 2019-04-30
SI3456831T1 (sl) 2021-11-30
US20210301301A1 (en) 2021-09-30
SG11201508028QA (en) 2015-10-29
EP2986729A4 (en) 2016-10-19
CN105308184A (zh) 2016-02-03
BR112015026197A2 (pt) 2017-10-10
KR20200136508A (ko) 2020-12-07
AU2020233694A1 (en) 2020-10-08
HUE040575T2 (hu) 2019-03-28
US10385359B2 (en) 2019-08-20
PT2986729T (pt) 2018-11-30
CA2908697A1 (en) 2014-10-23
CY1124627T1 (el) 2022-07-22
CA2908697C (en) 2023-12-12
AU2014253942B9 (en) 2020-08-13
EP3456831B1 (en) 2021-07-14
AU2014253942B2 (en) 2020-07-02
US10975390B2 (en) 2021-04-13
KR102186281B1 (ko) 2020-12-03

Similar Documents

Publication Publication Date Title
HRP20211385T8 (hr) Ciljana modifikacija genoma štakora
IL272193B (en) Genome engineering
HK1214627A1 (zh) 大鼠的遺傳修飾
IL245674A0 (en) Methods and preparations for the targeted modification of a genome
HK1202053A1 (en) Treatment of liver conditions
SG10202011533PA (en) Method of Viral Inhibition
HRP20181632T1 (hr) Postupci i kompoziti za ciljanu modificiranje genoma
IL233740A0 (en) Treatment of liver diseases
HK1170114A2 (en) One type of range hood
HK1198422A1 (en) Novel uses of colossolactones
GB201304608D0 (en) BenTime of Yisrael operable arrangement
TWM475821U (en) Structure of mosquito-catch
TWM475524U (en) Structure of rivet-pulling